Stanford Cancer Institute is convening its top cancer researchers on March 24, 2026, to showcase cutting-edge advances that could reshape how doctors treat melanoma, lung cancer, and solid tumors using immunotherapy and artificial intelligence. The annual Stanford Cancer Institute Research Conference brings together scientists working across basic research, translational science, clinical trials, and population health to present innovations that are moving from the laboratory into patient care. What New Approaches to Immunotherapy Are Stanford Researchers Developing? The conference agenda reveals several transformative directions in cancer immunotherapy. Researchers are focusing on engineering immune cells with enhanced anti-tumor activity, developing naturally orthogonal cytokines for T cell therapy, and creating comprehensive genetic manipulation strategies for cellular immunotherapies. One particularly promising area involves moving beyond traditional checkpoint inhibitors to explore new immune checkpoint blockade targets, such as ENNP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) for breast cancer treatment. For melanoma specifically, Stanford researchers are investigating functional biomarkers that could help doctors predict which patients will respond best to precision immunotherapy. This personalized approach aims to move beyond one-size-fits-all treatment protocols and instead match individual patients with therapies most likely to work for their unique tumor biology. Another major focus is solid tumor cell therapy, which represents a significant expansion beyond current CAR-T (chimeric antigen receptor T cell) therapies that have primarily succeeded in blood cancers. Researchers are working to overcome the unique challenges that solid tumors present, such as their ability to hide from immune cells and create immunosuppressive environments. How Are Artificial Intelligence and Genomics Changing Cancer Detection and Treatment Planning? Stanford's conference highlights a major shift toward AI-assisted decision-making in oncology. Researchers are developing multimodal AI-assisted tumor boards that combine imaging, genetic data, and clinical information to guide treatment decisions. This represents a move toward what experts call "digital twins" and real-world data integration, where AI models learn from actual patient outcomes to improve future recommendations. Genomic language modeling is emerging as a powerful tool for biological discovery. By treating genetic sequences similarly to how language models process text, researchers can identify patterns in DNA that predict drug resistance, tumor behavior, and treatment response. Additionally, researchers are conducting multiplexed functional lung cancer genomics, which allows them to test how multiple genetic changes affect tumor growth and drug sensitivity simultaneously. Steps to Understanding the Future of Precision Cancer Care - Functional Biomarkers: Stanford researchers are identifying specific biological markers that predict immunotherapy response in melanoma, moving beyond traditional staging systems to personalize treatment selection. - Engineered Immune Cells: Scientists are developing spatially targeted immune cells that can be directed to specific tumor locations, improving efficacy while reducing side effects on healthy tissue. - Next-Generation Engineered Proteins: Researchers are designing novel protein therapeutics that can be customized to target cancer cells more effectively than current antibody-based treatments. - AI-Assisted Tumor Boards: Multimodal artificial intelligence systems are being developed to synthesize imaging, genomic, and clinical data to guide oncologists toward optimal treatment decisions for individual patients. - Commensal Vaccines: Researchers are exploring how beneficial bacteria can be harnessed as cancer vaccines, representing a novel approach to stimulating anti-tumor immunity. The conference also features research into overcoming immune tolerance, where tumors develop mechanisms to evade the body's natural defenses. Stanford researchers are investigating how divergent evolution principles can be applied to design immune cells that adapt and overcome these resistance mechanisms. Beyond immunotherapy, researchers are developing clinical-stage oncology compounds that selectively target drug-resistant cancers. This addresses a critical problem in cancer treatment: tumors often develop resistance to initial therapies, requiring new approaches to overcome these adaptations. The Stanford Cancer Institute Research Conference, which has been held annually since 2007, serves as a hub for collaboration among cancer researchers across multiple disciplines. By bringing together experts in genomics, immunology, radiation oncology, surgery, and bioengineering, the conference accelerates the translation of laboratory discoveries into clinical applications that benefit patients. For patients and families navigating cancer treatment decisions, these advances suggest that future care will be increasingly personalized, with treatment selection guided by artificial intelligence analysis of individual tumor biology and immune function. The convergence of immunotherapy innovation, genomic precision, and AI-assisted decision-making represents a fundamental shift in how cancer is diagnosed, staged, and treated.
